Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study

Boogerd, Leonora S. F.; Hoogstins, Charlotte E.S.; Schaap, Dennis P.; Kusters, Miranda; Handgraaf, Henricus J.M.; Valk, Maxime J M van der; Hilling, Denise E.; Holman, Fabian A.; Peeters, Koen; Mieog, J. Sven D.; Velde, Cornelis J.H. van de; Fariña-Sarasqueta, Arantza; Lijnschoten, Ineke van; Framery, Bérénice; Pèlegrin, André; Gutowski, Marian; Nienhuijs, Simon W.; Hingh, Ignace H. J. T. de; Nieuwenhuijzen, Grard A. P.; Rutten, H.J.T.; Cailler, Françoise; Burggraaf, Jacobus; Vahrmeijer, Alexander L.

doi:10.1016/s2468-1253(17)30395-3

Cited by 162 publications

(141 citation statements)

References 31 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…EpCAM and CEA seem of particular interest for clinical translation given our current findings. Recently, a CEA-targeted fluorescent probe for intraoperative imaging, SGM-101, was validated in 26 patients with colorectal cancer [27] and 12 patients with pancreatic cancer [28]. Results indicated that the probe was safe and feasible for visualizing both primary adenocarcinomas and small metastases.…”

Section: Discussionmentioning

confidence: 99%

Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging

et al. 2020

View full text Add to dashboard Cite

Introduction Tumor-targeted imaging is a promising technique for the detection of lymph node metastases (LNM) and primary tumors. It remains unclear which biomarker is the most suitable target to distinguish malignant from healthy tissue in esophageal adenocarcinoma (EAC).Objective We performed an immunohistochemistry study to identify viable tumor markers for tumor-targeted imaging of EAC. Methods We used samples from 72 patients with EAC to determine the immunohistochemical expression of ten potential tumor biomarkers for EAC (carbonic anhydrase IX [CA-IX], carcinoembryonic antigen [CEA], hepatic growth factor receptor, epidermal growth factor receptor, epithelial membrane antigen [EMA], epithelial cell adhesion molecule [EpCAM], human epidermal growth factor receptor 2 [HER-2], urokinase plasminogen activator receptor, vascular endothelial growth factor-A [VEGF-A], and VEGF receptor 2). Immunohistochemistry was performed on tissue microarrays of LNM (n = 48), primary EACs (n = 62), fibrotic tissues (n = 11), nonmalignant lymph nodes (n = 24), and normal esophageal and gastric tissues (n = 40). Tumor marker staining was scored on intensity and percentage of positive cells. Results EMA and EpCAM showed strong expression in LNM (> 95%) and primary EACs (> 95%). Significant expression was also observed for LNM and EAC using VEGF-A (85 and 92%), CEA (68 and 54%), and CA-IX (4 and 34%). The other tumor biomarkers showed expression of 0-15% for LNM and primary EAC. Except for VEGF-A, nonmalignant lymph node staining was scored as slight or absent. Conclusions High expression rates and correlation between LNM in EAC combined with low expression rates in healthy lymph nodes and esophagus tissues were observed for EpCAM and CEA, meaning these are promising targets for tumortargeted imaging approaches for lymph nodes in patients with EAC. Key PointsThe use of intraoperative targeted imaging to detect lymph node metastases is promising and will be an important step forward in personalizing the surgical treatment of patients with esophageal cancer.The most suitable biomarker for targeted imaging techniques in lymph node metastases of esophageal adenocarcinoma remains unclear.Histological evaluation shows that epithelial cell adhesion molecule and carcinoembryonic antigen are suitable targets for image-guided esophageal surgery, both before and after neoadjuvant chemoradiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Components Of Molecular Imagingmentioning

confidence: 99%

“…Recently, Boogerd and co‐workers demonstrated the first clinical use of targeting carcinoembryonic antigen (CEA) for the detection of CRC during surgery . Apart from the potential for visualization of malignant lesions by CEA‐targeted molecular imaging, the fluorescent anti‐CEA monoclonal antibody SGM 101 was tested for its tolerability in patients by including a dose‐escalated cohort and appeared safe even at a maximum dose of 10 mg of SGM 101 . Therefore this approach opens the possibility that CEA‐targeted detection of CRC through molecular imaging can unmask otherwise invisible tumors during fluorescent‐guided surgery and can potentially influence clinical decision making .…”

Section: Components Of Molecular Imagingmentioning

confidence: 99%

“…43 Therefore this approach opens the possibility that CEAtargeted detection of CRC through molecular imaging can unmask otherwise invisible tumors during fluorescentguided surgery and can potentially influence clinical decision making. 43 However, the visualization of cancer cells by molecular imaging is not limited to the lower GI tract. In this regard, various landmark studies have impressively demonstrated that molecular imaging can also unmask (pre)neoplastic lesions in the esophagus [44][45][46][47] and therefore, clinical applications of molecular imaging can prospectively enable rapid and accurate diagnosis during early endoscopic or surgical procedures.…”

Section: Molecular Imaging Of Sporadic Colorectal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Molecular imaging within the lower gastrointestinal tract: From feasibility to future

Räth

Kießlich

Atreya

2018

Digestive Endoscopy

View full text Add to dashboard Cite

Molecular imaging is based on the labelling of defined molecular targets through the utilization of fluorescently linked probes and their subsequent detection with high-resolution endoscopic devices, thereby enabling visualization of single molecules including receptors. Whereas early studies have used molecular imaging for improved visualization and detection of early dysplasia and cancer as well as for assessing intestinal inflammation and inflammation-associated cancer within the gastrointestinal (GI) tract, more recent studies have impressively demonstrated that molecular imaging can also be used to characterize and visualize the molecular fingerprint of cancer and inflammation in vivo and in real time. With this, molecular imaging can be used to guide expression-tailored individualized therapy. With the rapid expansion and diversification of the repertoire of biological agents utilized in inflammatory bowel disease and cancer, this approach is gaining increasing attention. Within this review, we first summarize the technical components commonly used for molecular imaging and then review preclinical and clinical studies and evolving clinical applications on molecular imaging within the lower GI tract. Molecular imaging has the potential to significantly change endoscopic diagnosis and subsequent targeted therapy of gastrointestinal cancer and chronic gastrointestinal diseases.

show abstract

“…Near‐infrared (NIR) fluorescence imaging techniques using tumour‐targeting tracers may aid in this respect. In recent years, fluorescence‐guided surgery has gained interest, and has been able to provide surgeons with real‐time feedback and visualization of malignant tissues. SGM‐101, a carcinoembryonic antigen (CEA)‐specific tumour‐targeted fluorescent agent, can be used for fluorescence imaging to identify malignant tissue of colorectal origin.…”

Section: Introductionmentioning

confidence: 99%

Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer

Schaap

Valk

Deken

et al. 2020

British Journal of Surgery

View full text Add to dashboard Cite

This multicentre pilot study investigated the role of peroperative carcinoembryonic antigen (CEA)‐specific fluorescence imaging during cytoreductive surgery–hyperthermic intraperitoneal chemotherapy surgery in peritoneal metastasized colorectal cancer. A correct change in peritoneal carcinomatosis index (PCI) owing to fluorescence imaging was seen in four of the 14 included patients. The use of SGM‐101 in patients with peritoneally metastasized colorectal carcinoma is feasible, and allows intraoperative detection of tumour deposits and alteration of the PCI. Augmented reality guidance

show abstract

Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study

Cited by 162 publications

References 31 publications

Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging

Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging

Molecular imaging within the lower gastrointestinal tract: From feasibility to future

Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer

Contact Info

Product

Resources

About